News for Recursion Pharmaceuticals, Inc. (RXRX)

The U.S. stock market ended Friday, June 6, 2025, with substantial gains across all major indexes, as investors responded positively to better-than-expected

The U.S. stock market rallied strongly on Friday, June 6, 2025, with the S&P 500 breaking above the 6,000 level for the first time since February. As of

PR NewswireVANCOUVER, BC, June 4, 2025 Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, BC, June 4, 2025 /PRNewswire/ --

Market Analysis by covering: NVIDIA Corporation, Nebius Group NV, Recursion Pharmaceuticals Inc, Applied Digital Corp. Read 's Market Analysis on Investing.com

Recursion Pharmaceuticals (RXRX) experienced a significant decline in its stock price, falling by 11.36%. This sharp drop in share value occurred amidst broader

**media[615880]**

Bank of America has revised its price target for Recursion Pharmaceuticals (RXRX), reducing it to $8 from the previous $10. This decision follows the announceme

In recent developments concerning Recursion Pharmaceuticals (RXRX), analyst Gil Blum from Needham has made updates to the company's stock ratings and price targ

Cash Position: Ended the quarter with $509 million in cash.Cash Burn: $118 million during Q1 2025, including cash operating expenses and capital expenditures.C

May 05, 2025 / 12:00PM GMTChristopher Gibson - Recursion Pharmaceuticals Inc - Chief Executive Officer, Director Hi, everybody. My name is Chris Gibson, Co-Foun

Recursion Pharmaceuticals (RXRX) experienced a significant stock decline of 15.63% following the release of its first-quarter earnings and business update. This

Key Highlights: Recursion Pharmaceuticals is advancing its drug discovery platform, boosting research efficiency. The company has a robust cash position

Recursion Pharmaceuticals focuses on innovative drug discovery with a streamlined R&D pipeline in oncology and rare diseases.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Results Conference Call May 5, 2025 8:00 AM ETCompany ParticipantsChris Gibson - Co-Founder &...

Recursion (RXRX) is set to unveil initial findings from its ongoing TUPELO clinical trial at the 2025 Digestive Disease Week conference. This Phase 1b/2 trial i

Recursion Pharmaceuticals (RXRX) reachead $5.41 at the closing of the latest trading day, reflecting a -1.64% change compared to its last close.

Recursion (RXRX) has entered into a strategic licensing agreement with HealthVerity to incorporate its comprehensive real-world data into Recursion's clinical t

\n Recursion (RXRX) partners with HealthVerity to enhance clinical trial capabilities with real-world data. Access to de-identified data covering 340 milli

We recently published a list of Tech Firms Dominate Monday’s 10 Worst Performers.